Classical Hodgkin LymphomaSymptoms, Doctors, Treatments, Advances & More
Classical Hodgkin Lymphoma Overview
Learn About Classical Hodgkin Lymphoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
City Of Hope - Duarte Main Campus
Alex Herrera is an Oncologist practicing medicine in Duarte, CA. He has been practicing medicine for over 17 years. Dr. Herrera is rated as an Elite provider by MediFind in the treatment of Classical Hodgkin Lymphoma. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Colonoscopy. Dr. Herrera is board certified in American Board Of Internal Medicine, Hematology and American Board Of Internal Medicine, Oncology.
Matthew Genyeh Mei, M.D.
Matthew Mei is an Oncologist practicing medicine in Duarte, California. Dr. Mei is rated as an Elite provider by MediFind in the treatment of Classical Hodgkin Lymphoma. He is also highly rated in 39 other conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Colonoscopy.
Stanford University
Ranjana Advani is an Oncologist practicing medicine in Palo Alto, California. She has been practicing medicine for over 44 years. Dr. Advani is rated as an Elite provider by MediFind in the treatment of Classical Hodgkin Lymphoma. She is also highly rated in 26 other conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, and Tissue Biopsy.
Summary: The goal of this clinical research study is to learn if nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) can help to control newly diagnosed early-stage non-bulky cHL in pediatric, adolescent, and young adult patients. The safety of this drug combination will also be studied.
Summary: This phase II trial tests how well pembrolizumab in addition to chemotherapy (gemcitabine, brentuximab vedotin, and dacarbazine) works in treating frail patients with newly diagnosed Hodgkin lymphoma who aren't candidates for standard anthracycline-based treatment. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfer...
